These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38258434)

  • 1. Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
    Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
    Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38258434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF; Jia B; Xie L; Valenzuela GJ; Keystone EC; Li Z; Quebe AK; Griffing K; Otawa S; Haraoui B
    Rheumatol Ther; 2021 Jun; 8(2):987-1001. PubMed ID: 34028703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
    Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
    Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials.
    Fautrel B; Wu J; Wang D; Haladyj E; van de Laar MAFJ; Takeuchi T
    J Clin Rheumatol; 2023 Apr; 29(3):139-144. PubMed ID: 36473106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
    Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
    Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
    Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
    Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
    Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids.
    van Vollenhoven R; Helt C; Arora V; Zhong J; Correia AP; de la Torre I; Muram D
    Rheumatol Ther; 2018 Dec; 5(2):525-536. PubMed ID: 30357613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
    Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
    Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
    Fleischmann R; Takeuchi T; Schiff M; Schlichting D; Xie L; Issa M; Stoykov I; Lisse J; Martinez-Osuna P; Rooney T; Zerbini CAF
    Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1112-1121. PubMed ID: 31233281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
    Guidelli GM; Viapiana O; Luciano N; De Santis M; Boffini N; Quartuccio L; Birra D; Conticini E; Chimenti MS; Bazzani C; Bruschi E; Riva M; Canziani LM; Bianchi G; Pozzi MR; Limonta M; Gorla R; Perricone R; Frediani B; Moscato P; De Vita S; Dagna L; Rossini M; Selmi C
    Clin Exp Rheumatol; 2021; 39(4):868-873. PubMed ID: 33338001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
    Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
    Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
    Yang Y; Li XF; Zhang X; Bao CD; Hu JK; Xu JH; Li XP; Xu J; He DY; Li ZJ; Wang GC; Wu HJ; Ji F; Zhan LJ; Zerbini CAF; Li ZG
    Rheumatol Ther; 2020 Dec; 7(4):851-866. PubMed ID: 32876903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience.
    Tesei G; Cometi L; Nacci F; Terenzi R; Tofani L; Capassoni M; Bartoli F; Fiori G; Matucci-Cerinic M; Bruni C
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211014019. PubMed ID: 34025783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.
    van der Heijde D; Schiff M; Tanaka Y; Xie L; Meszaros G; Ishii T; Casillas M; Ortmann RA; Emery P
    RMD Open; 2019; 5(1):e000898. PubMed ID: 31168413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
    Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
    Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.